K. Frankowski

Depression of intracranial self-stimulation in male and female rats by intraperitoneal lactic acid: effects of morphine, ketoprofen, and interactions with G-protein biased kappa opioid agonists
20250 citationsauthor #3
Structure–Activity Relationships of a Brain-Penetrant D3 Dopamine Receptor Negative Allosteric Modulator and Investigation of its Binding Site
20230 citationsauthor #13
Discovery of FERM domain protein–protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer’s disease
202311 citationsauthor #36
Advances in Sulfonamide Kappa Opioid Receptor Antagonists: Structural Refinement and Evaluation of CNS Clearance.
20224 citationsauthor #3
Synthesis of (±)‐Physovenine via Electrochemical C–O Bond Formation
20221 citationsauthor #2
Structure–Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site
20220 citationsauthor #13
Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.
202215 citationsauthor #1
Divergent Electrochemical Carboamidation of Cyclic Amines.
20226 citationsauthor #2
Small-Molecule Disruptors of Mutant Huntingtin-Calmodulin Protein-Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin.
20225 citationsauthor #8
Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology
20225 citationsauthor #6
AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery
20214 citationsauthor #6
Structure–activity relationship investigation of triazole-based kappa opioid receptor agonists
20212 citationsauthor #1
Generation of the AD Informer Set: Chemical tools to facilitate Alzheimer’s disease drug discovery
20211 citationsauthor #12
Characterization of a D1 Dopamine Receptor Positive Allosteric Modulator with a Novel Binding Site
20211 citationsauthor #5
Discovery of sultam-containing small-molecule disruptors of the huntingtin–calmodulin protein–protein interaction
20202 citationsauthor #5
Development of Pyrimidone D1 Dopamine Receptor Positive Allosteric Modulators.
20207 citationsauthor #7
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion
20200 citationsauthor #21
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion
202011 citationsauthor #21
Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site
20200 citationsauthor #12
Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.
202019 citationsauthor #14
Mutant Huntingtin‐Calmodulin Interaction: Potential Therapeutic Target for Huntington's Disease
20190 citationsauthor #5
Identification of a Novel Negative Allosteric Modulator of the D3 Dopamine Receptor
20190 citationsauthor #9
Comparative Pharmacology and Structure–Activity Relationships of D1 Dopamine Receptor Positive Allosteric Modulators
20190 citationsauthor #4
Selective inhibition of metastasis in vivo, partly through disruption of nucleoli
20190 citationsauthor #1
Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor
201815 citationsauthor #12
Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites
201837 citationsauthor #15
In vivo Behavioral Characterization of ML417, a Novel D3 Dopamine Receptor‐selective Agonist
20180 citationsauthor #7
Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer
201813 citationsauthor #8
Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis
201864 citationsauthor #1
Positive Allosteric Modulators of the D1 Dopamine Receptor Act at Diverse Binding Sites
20181 citationsauthor #8
Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.
201716 citationsauthor #16
Discovery and Optimization of ML417: A Potent and Highly Selective D3 Dopamine Receptor Agonist
20170 citationsauthor #12
Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids
201615 citationsauthor #6
Synthesis of Kappa Opioid Antagonists Based On Pyrrolo[1,2-α]quinoxalinones Using an N-Arylation/Condensation/Oxidation Reaction Sequence.
20169 citationsauthor #3
Cover Picture: Evaluating p97 Inhibitor Analogues for Potency against p97–p37 and p97–Npl4–Ufd1 Complexes (ChemMedChem 9/2016)
20161 citationsauthor #4
Characterization of Novel Biased KOR Agonist‐Mediated Cell Signaling
20160 citationsauthor #4
Identification of a novel negative allosteric modulator of the D3 dopamine receptor
20160 citationsauthor #9
Evaluating p97 Inhibitor Analogues for Potency against p97–p37 and p97–Npl4–Ufd1 Complexes
201615 citationsauthor #4
Structurally Diverse Positive Allosteric Modulators of the D1 Dopamine Receptor Potentiate G‐Protein and β‐Arrestin‐Mediated Signaling
20161 citationsauthor #7
Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples.
20166 citationsauthor #3
Practical Electrochemical Anodic Oxidation of Polycyclic Lactams for Late Stage Functionalization.
201567 citationsauthor #1
Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase.
201562 citationsauthor #7
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.
20158 citationsauthor #1
Abstract 5368: Metarrestin effectively disassembles PNCs and inhibits metastasis
20150 citationsauthor #2
Development of Structure‐Activity Relationships for a G protein‐Biased Agonist of the D2 Dopamine Receptor
20150 citationsauthor #7
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias.
201556 citationsauthor #2
High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors.
201523 citationsauthor #18
Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.
20159 citationsauthor #10
Evaluating p97 Inhibitor Analogues for Their Domain Selectivity and Potency against the p97–p47 Complex
201530 citationsauthor #6
Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.
201543 citationsauthor #2
High‐throughput screening for identification of novel allosteric modulators of the D3 dopamine receptor
20150 citationsauthor #13
Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
201527 citationsauthor #4
Characterization of the kappa opioid receptor‐mediated G protein signaling in mouse striatum using a [35S]GTPγS binding assay (659.6)
20140 citationsauthor #5
Identification of a novel, highly potent D3 dopamine receptor‐selective agonist (662.8)
20140 citationsauthor #10
Discovery and characterization of a G protein‐biased agonist of the D2 dopamine receptor (662.7)
20140 citationsauthor #16
Table 10, Comparison of known inhibitors of p97ATPase with DBeQ, CID 49830258 [ML240], and CID 49830260 [ML241]
20130 citationsauthor #5
Figure 7, [(A) The NCI Mechanistic Set...].
20130 citationsauthor #2
Primuline Derivatives That Mimic RNA to Stimulate Hepatitis C Virus NS3 Helicase-catalyzed ATP Hydrolysis*
201310 citationsauthor #5
Figure 8, Structures of the isolated components of thioflavine S (T) and primuline (P)
20130 citationsauthor #2
Figure 18, P2 and amide derivative substructures used in SciFinder searches
20130 citationsauthor #2
Figure 3, General synthetic route for preparing probe compound SID 114279600 (CID 50930730) and associated analogues
20130 citationsauthor #2
Table A6, Critical reagents for the HCV subgenomic replicon assay
20130 citationsauthor #2
Figure 7, Proton NMR spectrum for SID 103904185 (CID 49830260)
20130 citationsauthor #5
Table D1, Description of the outcome for the screen of 827 compounds from the NCI DTP compound collection
20130 citationsauthor #2
Table 6, SAR analysis of primuline P2 amide derivatives for NS3 helicase inhibitor discovery
20130 citationsauthor #2
Table 9, Summary of in vitro ADMET/T Properties for p97ATPase probe(s)
20130 citationsauthor #5
Figure 14, General synthetic route for preparing probe compound SID 103904185 (CID 49830260) and associated analogues
20130 citationsauthor #5
Development of biased agonists at the kappa opioid receptor.
20132 citationsauthor #4
Scheme 1, [Reagents: (a) substituted benzoyl chloride,...].
20130 citationsauthor #2
Table 4, Probe and analogue submissions to MLSMR (BioFocus DPI) for NS3 helicase inhibitor discovery
20130 citationsauthor #2
Figure 11, Stability for compound SID 103904169 (CID 49830258) in 100% aqueous and 50% acetonitrile/aqueous
20130 citationsauthor #5
Table 2, Critical reagents for the p97 ATPase dose response assay
20130 citationsauthor #5
Figure 11, Compound interaction with the partially duplex helicase DNA substrate
20130 citationsauthor #2
Table A1, Critical reagents for the helicase assays
20130 citationsauthor #2
Figure 22, CID 50930749 location in cells
20130 citationsauthor #2
Table A8, Critical reagents for the Cellular HCV RNA quantification assay
20130 citationsauthor #2
Figure B1, Proton NMR spectrum for SID 114279600 (CID 50930730)
20130 citationsauthor #2
Table 1, Inhibitors of NS3 helicase known at the time of grant award
20130 citationsauthor #2
Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase
2013135 citationsauthor #3
Table 6, Probe ML240 and analog submissions to MLSMR (BioFocus DPI) for reversible inhibitors of p97
20130 citationsauthor #5
Figure 25, Effect of compounds on the polarization of a Cy5-dT15-E. coli single-stranded DNA binding protein (SSB) complex
20130 citationsauthor #2
Table 7, SAR analysis of additional P2 derivatives for NS3 helicase inhibitor discovery
20130 citationsauthor #2
Table 5, Isolated thioflavine S and primuline components for NS3 helicase inhibitor discovery
20130 citationsauthor #2
Table 4, Caspase 3/7 activation in response to p97 inhibition assay
20130 citationsauthor #5
Helicase-catalyzed ATP Hydrolysis Stimulate Hepatitis C Virus NS 3 Primuline Derivatives That Mimic RNA to Enzymology :
20130 citationsauthor #5
Figure 20, Effect of ML283, CID 50930749, and interferon on cellular HCV RNA levels
20130 citationsauthor #2
Figure 3, Proton NMR spectrum for SID 103904169 (CID 49830258)
20130 citationsauthor #5
Figure 10, Structures of representative DNA binding agents
20130 citationsauthor #2
Table A5, Critical reagents for the E. coli SSB DNA binding assay
20130 citationsauthor #2
Table 11, Summary of in vitro ADME properties of ML283 CID 50930730
20130 citationsauthor #2
Figure 6, HRMS data for SID 103904169 (CID 49830258); HRMS (ESI) m/z calcd for C23H21N6O ([M+H]+), 397.1777, found 397.1776
20130 citationsauthor #5
Figure 17, Summary of the SAR strategy to synthesize analogues based on the hit, P3
20130 citationsauthor #2
Table A4, Critical reagents for the NS3 protease assay
20130 citationsauthor #2
Figure 16, Structures of derivatives based on the major components in primuline
20130 citationsauthor #2
Figure 23, Use of fluorescence microscopy to visualize CID 50930730/ML283 in cells
20130 citationsauthor #2
Selective, reversible inhibitors of the AAA ATPase p97
20136 citationsauthor #5
Figure 21, Effect of CID 50930749 on the cellular location of HCV Replication complexes seen in the replicon-containing Huh7.5/Con1sg-Rluc cells
20130 citationsauthor #2
Table A3, Critical reagents for the ATP hydrolysis assays
20130 citationsauthor #2
Figure B3, LCMS purity data at 214 nm for SID 114279600 (CID 50930730); LCMS retention time: 2.68; purity at 214 nm = 93.6%
20130 citationsauthor #2
Table 9, SAR analysis of selected fully synthetic analogues for NS3 helicase inhibitor discovery
20130 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT